Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
Brooklyn ImmunoTherapeutics, Inc. recently announced 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience and exclusively licensed to Brooklyn for various fields of therapeutic use. The newly-issued patents encompass those covering the company’s mRNA-based cellular reprogramming and gene editing technology, as well as nucleic acid delivery using Brooklyn’s ToRNAdo lipid nanoparticle technology (LNP).
“We believe that the newly issued patents reflect the exceptional and innovative work in advancing mRNA-based technologies conducted by our partners at Factor Bioscience. Additionally we believe that Brooklyn’s exclusive license to these and previously issued Factor patents, now numbering more than 70 total issued patents, position us to execute our programs in multiple important therapeutic areas and make us a good strategic partner for other companies that wish to work in the engineered cellular therapy field,” said Brooklyn’s Chief Executive Officer and President Howard Federoff, MD, PhD. “Moreover, there are greater than 60 pending patent applications which provide the opportunity for further broadening the scope of technology controlled by Brooklyn for developing transformative regenerative medicines.”
Many of the newly-issued patents are directed to compositions and methods for reprogramming somatic cells to pluripotent stem cells and using mRNA-based methods to direct gene editing. Other newly-issued patents are directed to a novel LNP that efficiently delivers nucleic to cells both in vitro and in vivo. The new patents have been issued in the United States, Australia, Japan, Korea, Hong Kong, and eight European countries, including France and Great Britain and have expiry dates that extend to 2032 or beyond.
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information, visit www.BrooklynITx.com.
Total Page Views: 867
